NCT03433001 · FLOW

Participant flow

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone · Source last updated 2023-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Participants took ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone were not defined by the protocol but according to the package insert of each drug.
id
FG000
title
Ixazomib + Lenalidomide + Dexamethasone

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
109
type
Lack of Efficacy
reasons
group Id
FG000
num Subjects
69
type
Adverse Event
reasons
group Id
FG000
num Subjects
10
type
Withdrawal by Subject
reasons
group Id
FG000
num Subjects
12
type
Death
reasons
group Id
FG000
num Subjects
4
type
Lost to Follow-up
reasons
group Id
FG000
num Subjects
25
type
Other
milestones
achievements
group Id
FG000
num Subjects
295
type
STARTED
achievements
group Id
FG000
num Subjects
66
type
COMPLETED
achievements
group Id
FG000
num Subjects
229
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

A total of 295 participants were enrolled and received the study treatment in this study.

recruitment Details

Participant s took part in the survey at 101 investigative sites in Japan, from 2 April 2018 to 11 June 2021.

Complete source fields